{
    "nct_id": "NCT03891901",
    "official_title": "IMPACT-TB (Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB): A Phase II Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin",
    "inclusion_criteria": "* Adult age between 18 years and 55 years\n* Body mass index (BMI) greater than 18.5 kg/m^2\n* At least 8 years formal education, with appropriate reading and comprehension skills\n* Able and willing to provide written informed consent\n* Males must agree to using contraception during the study and for 2 weeks after the last dose of study drug.\n* If a female participant is of reproductive potential, the participant (and her partner) must agree to use of one of the following combinations of birth control during the study and for 2 weeks after the last dose of study drug (or tubal ligation as a single method):\n\n  * Use of a double-barrier method of contraception: condoms (male or female) and a diaphragm or cervical cap with spermicide;\n  * Use of an intrauterine device (IUD) and a barrier method: condoms (male or female, with or without spermicide) or a diaphragm or cervical cap with spermicide;\n  * For those in the imatinib only study arms: use of hormone-based contraceptives (pill, patch, implant, ring, or injectable) and a barrier method: condoms (male or female, with or without spermicide) or a diaphragm or cervical cap with spermicide (participants in study arms receiving isoniazid and rifabutin are not eligible if they are relying hormonal contraceptives other than an IUD)\n  * Tubal ligation.\n  * Women who are post-menopausal, defined as age greater than 45 and no menses for at least 1 year, or who have had a hysterectomy, are considered not of reproductive potential.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Current or imminent treatment for significant infection\n* Pregnant or breastfeeding\n* HIV positive status as determined by a U.S. Food and Drug Administration (FDA)-approved HIV assay\n* Hepatitis B infection, as determined by an FDA-approved hepatitis B surface antigen assay\n* Hepatitis C infection, as determined by an FDA-approved positive Hepatitis C antibody assay\n* Known infection with Mycobacterium tuberculosis (MTB)\n* History of allergy or hypersensitivity to imatinib, isoniazid or rifabutin.\n* History of enrollment in other clinical trials with investigational agents within 8 weeks\n* Cardiac arrhythmia requiring medication, or any clinically significant electrocardiogram (ECG) abnormality\n* Exam consistent with congestive heart failure (e.g., edema)\n* Random blood glucose greater than 140 mg/dL or history of unstable diabetes mellitus requiring hospitalization for hyper or hypoglycemia within the past year prior to start of screening\n* Use of systemic corticosteroids within the past 28 days\n* Any of the following readings from a complete blood count that fall outside the normal ranges as listed here:\n\n  * White blood cell count: 3.4 10E3/microliter (mcL) - 11 10E3/mcL\n  * Hemoglobin: Female- 11.1 - 16.7 gm/dL, Male- 12.5 - 16.5 gm/dL\n  * Platelet count: 150-400 10E3/mcL\n  * Absolute neutrophil count: Female- 0.91-5.53 10E3/mcL, Male- 0.67-6.41 10E3/mcL\n  * Absolute lymphocyte count: Female- 0.65-3.05 10E3/mcL, Male- 0.72-3.29 10E3/mcL\n* Any of the following chemistry panel and liver function test readings that fall outside the normal ranges as listed here:\n\n  * Serum potassium: 3.5-5.4 mmol/L\n  * Alkaline phosphatase (ALP): 34 - 104 unit/L\n  * Alanine aminotransferase (ALT): 4 - 52 unit/L\n  * Aspartate aminotransferase (AST): 13 - 39 unit/L\n  * Total Bilirubin: 0.2 - 1.0 mg/dL\n  * Creatinine: Female- 0.60-1.20 mg/dL, Male- 0.7-1.3mg/dL\n* Cirrhosis of the liver, or any known active or chronic liver disease\n* Current or past alcohol or elicit/recreational drug use, which in the expert judgment of the Investigator, will interfere with the participant's ability to comply with the protocol requirements.\n* Any experimental medications for less than 8 weeks prior to screening or anticipated use during the trial\n* Current (within 30 days prior to the first dose of study drug) or anticipated use of antimetabolites; alkylating agents; or other drugs or herbal preparations (including St. John's wort), known to affect activity of the CYP3A4 enzyme pathway\n* Consumption of grapefruit, grapefruit juice, or grapefruit-related citrus fruits (e.g., pomelos) within 7 days before assessment for eligibility\n* Unwilling to avoid grapefruit or grapefruit-related citrus fruits/pomelo during the course of the study\n* Unwilling to avoid alcohol for the duration of the study\n* Unwilling to abstain from taking acetaminophen-containing medications during the 28-day study drug dosing period, due to increased risk of liver toxicity\n* History of major medical disorders including metabolic, endocrine, hypothyroid, hepatic, renal, hematologic, pulmonary, gastrointestinal, autoimmune or cardiovascular disorders\n* Uncontrolled hypertension (persistent measurements at or above 150/100)\n* Participants who are, in the opinion of the Investigator, unable to comply with the dosing schedule and protocol evaluations\n* Diarrhea defined as 4 or more stools per day\n* Active involvement (by the participant or the participant's partner) in In Vitro Fertilization or another assisted reproductive technology procedure\n* Emory students currently enrolled in a course taught by the principal investigator (PI) or a Co-Investigator\n* Emory employees currently working under supervision of the PI or a Co-Investigator",
    "miscellaneous_criteria": ""
}